30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Acrivon Therapeutics Inc (ACRV)

Track

The most recent insider trading activity occurred on January 14, 2026, with executive purchases totaling $97,123.39. Prior to this, significant selling activity was observed in April 2025 by PERCEPTIVE ADVISORS LLC, and earlier in June 2023 by Chione Ltd. The latest transactions indicate insider confidence.
Stock chart
Ticker: ACRV Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Levy Adam D.
Chief Financial Officer
1 purchase — total 14,999 USD
Buy 14 Jan 2026
Value US$2,175,974.09 | Price 80.22 | Shares 61,701
Buy 14 Jan 2026
Value US$4,928,519.28 | Price 34.49 | Shares 15,216
Buy 13 Jan 2026
Value US$17,218.00 | Price 1.72 | Shares 10,000
Sale 1 May 2025
Value US$400,507.24 | Price 1.34 | Shares 298,886
Sale 30 Apr 2025
Value US$617,412.21 | Price 1.41 | Shares 437,881
Sale 29 Apr 2025
Value US$352,500.00 | Price 1.41 | Shares 250,000
Sale 28 Apr 2025
Value US$335,841.48 | Price 1.56 | Shares 215,283
Sale 25 Apr 2025
Value US$2,056,604.55 | Price 1.95 | Shares 1,054,669
Buy 11 Apr 2024
Value US$20,000,500.00 | Price 8.50 | Shares 2,353,000
Sale 26 Jun 2023
Value US$206.88 | Price 12.93 | Shares 16
Sale 15 Jun 2023
Value US$24,959.84 | Price 12.14 | Shares 2,056
Sale 14 Jun 2023
Value US$10,832.09 | Price 12.13 | Shares 893
Sale 13 Jun 2023
Value US$36,900.00 | Price 12.30 | Shares 3,000
Sale 12 Jun 2023
Value US$24,680.00 | Price 12.34 | Shares 2,000
Proposed sale 12 Jun 2023
Value US$2,727,594.00 | Price 12.44 | Shares 219,259
Buy 17 Nov 2022
Value US$42,368,750.00 | Price 12.50 | Shares 3,389,500
Buy 17 Nov 2022
Value US$5,000,000.00 | Price 12.50 | Shares 400,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-16 2026-01-14 B Purchase
1.7
Levy Adam D.

Chief Financial Officer

Officer
61,701 +15.3%
80.22
US$2,175,974 		61,701 +15.3% 80.22 US$2,175,974
2026-01-16 2026-01-14 B Purchase
1.7
Blume-Jensen Peter

President and CEO

Executive Director
15,216 -14.0%
34.49
US$4,928,519 		15,216 -14.0% 34.49 US$4,928,519
2026-01-15 2026-01-13 B Purchase
1.5
Devroe Eric

Chief Operating Officer

Officer
74,449 -49.9%
346.54
US$4,549,334 		74,449 -49.9% 346.54 US$4,549,334
2025-05-01 2025-05-01 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
298,886 -8.8%
1.34
US$400,507 		298,886 -8.8% 1.34 US$400,507
2025-05-01 2025-04-30 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
437,881 -11.4%
1.41
US$617,412 		437,881 -11.4% 1.41 US$617,412
2025-04-29 2025-04-29 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
250,000 -6.1%
1.41
US$352,500 		250,000 -6.1% 1.41 US$352,500
2025-04-29 2025-04-28 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
215,283 -5.0%
1.56
US$335,841 		215,283 -5.0% 1.56 US$335,841
2025-04-29 2025-04-25 S Sale
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
1,054,669 -19.7%
1.95
US$2,056,605 		1,054,669 -19.7% 1.95 US$2,056,605
2024-04-15 2024-04-11 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
2,353,000 +78.2%
8.50
US$20,000,500 		2,353,000 +78.2% 8.50 US$20,000,500
2023-06-28 2023-06-26 S Sale
1.5
Chione Ltd
Large shareholder
16 -0.0%
12.93
US$207 		16 -0.0% 12.93 US$207
2023-06-20 2023-06-15 S Sale
1.5
Chione Ltd
Large shareholder
2,056 -0.1%
12.14
US$24,960 		2,056 -0.1% 12.14 US$24,960
2023-06-14 2023-06-14 S Sale
1.5
Chione Ltd
Large shareholder
893 -0.0%
12.13
US$10,832 		893 -0.0% 12.13 US$10,832
2023-06-14 2023-06-13 S Sale
1.5
Chione Ltd
Large shareholder
3,000 -0.1%
12.30
US$36,900 		3,000 -0.1% 12.30 US$36,900
2023-06-14 2023-06-12 S Sale
1.5
Chione Ltd
Large shareholder
2,000 -0.1%
12.34
US$24,680 		2,000 -0.1% 12.34 US$24,680
2023-06-12 2023-06-12 PrS Proposed sale
1.5
Chione Ltd

10% Stockholder

Large shareholder
219,259
12.44
US$2,727,594 		219,259 12.44 US$2,727,594
2022-11-21 2022-11-17 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
3,389,500 +340.8%
12.50
US$42,368,750 		3,389,500 +340.8% 12.50 US$42,368,750
2022-11-21 2022-11-17 B Purchase
1.5
Chione Ltd
Large shareholder
400,000 +11.6%
12.50
US$5,000,000 		400,000 +11.6% 12.50 US$5,000,000
Explore more

More insider trading research around Acrivon Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America